0000000001056911

AUTHOR

Gigi Vos

showing 1 related works from this author

Risk factors and molecular characterization of penile cancer

2020

Purpose of review To provide a comprehensive summary of risk factors, molecular machinery as well as potential therapeutic targets with a particular focus on literature published in the last 2 years on prognosis and treatment of penile cancer (PeCa). Recent findings E2F, LAMC2, MAML2, ID1 and IGFBP2 proteins were demonstrated to play a critical role for aggressive tumor behavior and might predict poor survival in PeCa. PD-L1 axis was confirmed as a promising pathway to serve as a therapeutic target. A number of genetic alterations were illuminated. In clinical testing, pan-HER tyrosine kinase inhibitor dacomitinib provided promising results in chemo-naive and EGFR monoantibody nimotuzumab i…

Oncologymedicine.medical_specialtybusiness.industrymedicine.drug_classUrology030232 urology & nephrologyIndividualized treatmentmedicine.diseaseSystemic therapyDacomitinibTyrosine-kinase inhibitorClinical trial03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisInternal medicineMonoclonalmedicineNimotuzumabPenile cancerbusinessmedicine.drugCurrent Opinion in Urology
researchProduct